By inactivating mitogen activated protein kinase (MAPK) kinase MAP2K6, overexpression of miR-625-3p in CRC cell induced resistance to oxaliplatin-based therapy (33). This evidence concerns the gene MAP2K6 and colorectal carcinoma.